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Abstract
Background: Receptor for advanced glycation end-products (RAGE), a receptor for amyloids, is constitutively expressed
in lungs and generally observed to be downregulated in lung cancer tissues. However, increasing levels of RAGE or serum
amyloids is associated with poor outcome in lung cancer patients. We report a rare case of primary systemic amyloid
light-chain (AL) amyloidosis in biopsy-proven multiple organs with early-stage non-small cell lung cancer (NSCLC) that
displayed strong staining for RAGE in the tumour tissue. Interestingly, compared with randomly selected lung cancer
biopsy samples, including all representative histological subtypes of NSCLC and small-cell lung cancer, only the NSCLC in
the present case showed strong expression for RAGE that can bind amyloids.
Case presentation: A 71-year-old woman was admitted to our hospital for comprehensive investigation of nephrotic
syndrome. Computed tomography showed a small nodule in the right upper lung lobe with hilar mediastinal lymph
node enlargement. Pathological examination of transbronchial biopsy samples of the nodule yielded a diagnosis of
lung adenocarcinoma. Furthermore, the pathological detection of amyloid deposition in biopsy samples of a subcarinal
lymph node, gastric and duodenal mucosa, cardiac muscle, and bone marrow led to a diagnosis of primary systemic AL
amyloidosis with nephrotic syndrome and cardiomyopathy. In addition, RAGE was detected in lung tumour tissues
surrounded by normal lung tissues with amyloid deposition.
Conclusion: The RAGE positivity of the lung cancer cells in this case suggests an interaction between amyloid-containing
tissues and RAGE-expressing cancer cells. Lung adenocarcinoma with RAGE expression may be a complication of
underlying amyloidosis.
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Background
The incidence of systemic amyloidosis in patients with
cancer is very rare and has been estimated to be between
0.1% and 0.4% among all cancers [1]. Increasing serum
amyloid A (SAA) level in a patient with non-small cell
lung cancer (NSCLC) is considered a predictive
biomarker of poor prognosis [2]. Receptor for advanced
glycation end-products (RAGE) is a transmembrane re-
ceptor of the immunoglobulin superfamily and binds
structurally diverse molecules, including amyloids.
RAGE is constitutively expressed in lungs and observed
to be downregulated in lung cancer patients. RAGE as-
sociates with survival and metastatic spread of cancers
[3, 4]. Herein, we report on a rare case of primary sys-
temic amyloid light-chain (AL) amyloidosis in biopsy-
proven multiple organs with early-stage NSCLC that dis-
played strong staining for RAGE in the tumour tissue.
* Correspondence: shinsaku@juntendo.ac.jp
1Department of Respiratory Medicine, Juntendo University School of
Medicine & Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo
113-8421, Japan
2Research Institute for Diseases of Old Ages, Juntendo University Graduate
School of Medicine, Tokyo, Japan
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Okamoto et al. BMC Cancer  (2017) 17:22 
DOI 10.1186/s12885-016-3009-3
Case presentation
A 71-year-old Japanese woman, non-smoker, with a his-
tory of cholelithiasis, hypertension, and dyslipidaemia,
was referred to our hospital for evaluation of nephrotic
syndrome. The patient had been diagnosed with hyper-
trophic cardiomyopathy 6 months previously.
On physical examination, the patient was 155.0 cm
tall. She weighed 46.0 kg and showed a systolic ejection
murmur from the left sternal border to the apex and pit-
ting leg oedema. The remainder of the examination was
unremarkable. On blood analysis, hypoalbuminemia
(1.7 g/dL), proteinuria (4.5 g/gCr), and serum IgG M-
protein were detected. Serum free light chain (SFLC)
assay showed an increase in free lambda chain with a de-
creased kappa/lambda ratio (kappa SFLC: 7.8 mg/L, nor-
mal 3.3–19.4 mg/L; lambda SFLC: 70.5 mg/L, normal
5.7–26.3 mg/L; kappa/lambda ratio: 0.11, normal 0.3–
1.3). On the other hand, SAA (5.6 μg/mL) and immuno-
globulin were within normal limits. Creatinine (0.8 mg/
dL), brain natriuretic peptide (325.8 pg/mL), and carci-
noembryonic antigen (6.4 ng/mL) were elevated. Chest
radiography showed a nodule, 2.1 cm in diameter, in the
right upper lung field. Computed tomography revealed a
nodule with marginal irregularity and bronchodilatation
in the right upper lobe, hilar mediastinal lymph node en-
largement, slight bilateral pleural effusion, pericardial ef-
fusion, and ascites (Fig. 1).
Pathological examination of transbronchial biopsy
samples of the lung nodule yielded a diagnosis of adeno-
carcinoma (Fig. 2a). In addition, interstitial deposition of
amorphous material that stained positively for Congo
red with apple-green birefringence in the polarized view,
and an amyloid P component was found in the tissues
surrounding the tumour and in the subcarinal lymph
node (Fig. 2f, j: lung; g, k: subcarinal lymph node). En-
largement of the subcarinal lymph node was not due to
cancer metastasis. In addition, biopsy samples of gastric
and duodenal mucosa, bone marrow, and cardiac muscle
stained positively for Congo red with apple-green bi-
refringence in the polarized view, and amyloid P compo-
nent (Fig. 2h, l: duodenal mucosa; i, m: bone marrow).
Only the subcarinal lymph node and the cardiac muscle
stained positively for anti-lambda light chain antibodies.
Furthermore, positive staining for RAGE was detected
only in the lung tumour cells (Fig. 2b-e). The bone mar-
row demonstrated a normal population of plasma cells
with slight atypia.
Finally, the case was diagnosed as lung adenocarcinoma,
Stage IA (cT1bN0M0), and primary systemic AL amyloid-
osis with nephrotic syndrome and cardiomyopathy.
Because the patient displayed rapidly worsening edema
and cardiac amyloidosis with elevated brain natriuretic
peptide, she was given a poor prognosis rather than that
expected with early-stage lung adenocarcinoma and was
treated with dexamethasone (20 mg/day) and diuretics.
The oedema, mainly due to the nephrotic syndrome
with severe proteinuria, pleural effusion, and brain natri-
uretic peptide levels were not responsive to treatment.
The patient died after 3 months despite dexamethasone
and bortezomib treatment in another hospital.
Discussion
RAGE is a multiligand receptor that binds structurally
diverse molecules, including high mobility group box 1,
S100 family of proteins, some species of advanced glyca-
tion end-products, and β-sheet fibrillar material (e.g.,
amyloid-β and SAA). RAGE is constitutively expressed
at high levels in alveolar-type cells and at relatively low
levels in vascular endothelial cells, inflammatory cells,
and neurons [4–6]. RAGE and its ligands are highly up-
regulated in cancer tissue (e.g., pancreatic, colon, and
prostate cancer) [7]. By contrast, both RAGE and serum
Fig. 1 Computed tomography (CT) images. a Chest CT scan showing the nodule with marginal irregularity and bronchodilatation in the right
upper lobe. b CT scan in the mediastinal window showing mediastinal lymph node enlargement and bilateral pleural effusion
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soluble RAGE (sRAGE) levels are downregulated in
smokers and lung cancer patients [7–9].
Interestingly, RAGE that can bind amyloids showed
strong expression in primary lung adenocarcinoma tis-
sue in the early stages (Fig. 2b) and negative expression
in other amyloid-positive tissues without metastasis such
as the subcarinal lymph node, duodenal mucosa, and bone
marrow (Fig. 2c, d, e). We confirmed RAGE staining in
lung cancer tissues without comorbidity of amyloidosis by
applying immunohistochemical analysis in randomly se-
lected biopsy samples of lung cancer, including all repre-
sentative histological subtypes of NSCLC and small-cell
lung cancer; these samples were used as the negative con-
trol (Fig. 3a-f).
Previous studies have reported that expression levels of
RAGE and its ligands are associated with clinical outcome
in patients with NSCLC. Upregulated RAGE expression
and activity are associated with tumour invasion and
Fig. 2 Microphotographs of the present case. a-b The lung adenocarcinoma (a, b: arrowheads): a haematoxylin and eosin staining (bar = 100 μm); b
receptor for advanced glycation end-products (RAGE) staining (bar = 100 μm). Positive staining for RAGE is seen. c-e RAGE staining of other tissues (bar
= 100 μm): c subcarinal lymph node; d duodenal mucosa; e bone marrow. None of these tissues show positive staining for RAGE. f-i Congo red staining
(bar = 200 μm): f lung tissue surrounding the adenocarcinoma; g subcarinal lymph node; h duodenal mucosa; i bone marrow. Amorphous deposition
was found in the tissues surrounding the tumour (f: arrowheads). j-m Amyloid P component staining (bar = 200 μm): j lung tissue surrounding the
adenocarcinoma; k subcarinal lymph node; l duodenal mucosa; m bone marrow. All amorphous material shows positive staining for Congo red with
apple-green birefringence in the polarized view, and amyloid P component
Fig. 3 Immunohistochemical staining for receptor for advanced glycation end-products (RAGE) in control lung cancers: a solid adenocarcinoma;
b acinar adenocarcinoma; c papillary adenocarcinoma; d lepidic adenocarcinoma; e squamous cell carcinoma; f small-cell carcinoma. All controls
stained negatively for RAGE (bar = 100 μm)
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metastatic activity in certain types of neoplasia, including
gastric and colon cancer [10, 11]. In contrast, overex-
pressed RAGE in lung cancer cells suppresses tumour
growth and the acquisition of cancer stem cell features in
vitro [12]. sRAGE traps circulating ligands that are over-
expressed in lung cancer and thus acts as an inhibitor of
RAGE-mediated cell signalling [13]. We were not able to
monitor the clinical time course of serum sRAGE level as
a surrogate marker in this case. There is speculation that
downregulation of both RAGE and sRAGE may be a crit-
ical step in the formation of lung tumours [8, 9, 14]. Sev-
eral genetic single nucleotide polymorphism (SNP) studies
identified that the SNPs in the RAGE associated with in-
creased NSCLC risk and a lower chemotherapy response
rate and poor prognosis [9, 15, 16]. In addition, increasing
concentrations of SAA corresponded to poor response to
tyrosine kinase inhibitors and correlated with poor clinical
outcome [2, 17]. In the present patient, the onset of lung
cancer appeared to match mostly with that of systemic AL
amyloidosis with increasing SFLC, regarded as the precur-
sor form of amyloid protein [18]. This case was not AA
amyloidosis but systemic AL amyloidosis; thus, SAA levels
were within normal limits.
The relationship between cancer and amyloidosis is
still unknown, as well as the relevance of amyloidosis as
a paraneoplastic syndrome induced by lung cancers.
However, 10 of 12 case reports, including the present
case, showed the diagnosed period of lung cancer to be
the same as or prior to that of amyloidosis (Table 1)
[19–29]. These clinical time courses suggest the prior
onset of lung cancer may contribute to the deposition of
amyloid through paraneoplastic mechanisms. In the
present case, the deterioration of cardiac amyloidosis
directly led to death, as a poorer prognostic factor than
early lung cancer itself. Generally, RAGE levels are
downregulated in lung cancer patients. However, our case
showed strong expression of RAGE that was surrounded
by lung tissue with amyloid deposition, even though the
patient had early-stage lung cancer (Fig. 2b, f ).
Thus, the RAGE positivity of lung cancer cells in this
case suggests an interaction between amyloid-containing
tissues and RAGE-expressing cancer cells, which may
progress both lung cancer and amyloidosis. Further
study is warranted to investigate this association.
Conclusion
We describe a rare case of amyloid receptor-positive
lung adenocarcinoma with systemic AL amyloidosis. Cli-
nicians should be aware that RAGE-positive lung cancer
may be a complication of underlying amyloidosis that
could impact more severely on the prognosis of the pa-
tient than the cancer itself.
Abbreviations
AL: Amyloid light-chain; NSCLC: Non-small cell lung cancer; RAGE: Receptor
for advanced glycation end-products; SAA: Serum amyloid A; SFLC: Serum












van Bronswijk et al.
1982 [19]
71/M SCLC, Advanced K AA Lung cancer Radiotherapy Pulmonary infection
Meyrier et al. 1985 [20] 59/M SCC, TbN1Mx A, K, SP AA Lung cancer CCRT Renal failure due to
amyloidosis
Focan et al. 1985 [21] 70/M SCC, Early BM, Digestive tract N/A Unknown None Pulmonary infection
Richmond et al. 1990
[22]
72/M SCC, Early Multiple organs AA Same None Peritonitis and Renal
failure due to amyloidosis
Benharroch et al. 1992
[23]
51/F AC, N/A F AL Unknown None Renal failure due to
systemic sclerosis
Partidge et al. 2000 [24] 69/M NSCLC, Stage IV Mediastinal LN N/A Same None NSCLC
Garthwhite et al. 2003
[25]
64/M SCC, N/A K, L AA Same Radiotherapy N/A
Barcelo et al. 2003 [26] 33/M SCC, Stage IIIB C, K AA Lung cancer Chemotherapy Pulmonary infection
Paydas et al. 2005 [27] 50/M AC, Stage IIIB K AA Lung cancer CCRT N/A
Miyazaki et al. 2011 [28] 60/M AC, Stage IA K, L, ST AL Same Surgery N/A
Gueutin et al. 2013 [29] 56/M AC, Stage IIIB K AA Lung cancer Chemotherapy N/A
Our case 2016 71/F AC, Stage IA D, H, K, L, ST AL Same None Heart failure due to
amyloidosis
A adrenal gland, AA amyloid A amyloidosis, AC adenocarcinoma, AL amyloid light-chain amyloidosis, BM bone marrow, C colon, CCRT concurrent chemoradiother-
apy, D duodenum, F female, H heart, K kidney, L lung, LN lymph node, M male, N/A not available, NSCLC non-small cell lung carcinoma, SCC squamous cell carcin-
oma, SCLC small-cell lung cancer, SP spleen, ST stomach, y years
a ‘Same’ refers to a diagnosis given at the same time as amyloidosis
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